Tirzepatide to slow plaque buildup in coronary arteries
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial studies tirzepatide to see if it can slow the progression of coronary artery plaque in people with type 2 diabetes. It uses special heart CT scans to track changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 40 and 80 years old
- You have type 2 diabetes for at least 5 years, with A1c between 7.0% and 10.5%
- Your BMI is 25 or higher
- Your CT heart scan shows two separate plaque spots in the coronary arteries with more than 20% blockage
- Your diabetes medicines have been stable for more than 4 weeks before starting the study
- If you use oral hormonal birth control, you must switch to non-pill contraception (or add barrier protection) during dose changes and for the stated extra weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This trial tests whether tirzepatide, a medication that helps control blood sugar and weight, can safely improve how your body handles sugar when you have type 1 diabetes. The study looks at short-term effects and may help people who are overweight and use an insulin pump or automated system.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests a once-weekly medicine called tirzepatide to see if it helps control blood sugar and reduce weight in people with type 2 diabetes and obesity. If you qualify, you might get this treatment and be monitored for safety and satisfaction.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.